Bio Protocol (@BioProtocol): Highlights and key takeaways from DeSci Singapore 2025 last week 👇

Highlights and key takeaways from DeSci Singapore 2025 last week 👇 → AI hits 70% accuracy in predicting negative chemical reactions (vs. 30% for humans). But humans still win on positives. Biggest bottleneck? No incentive to share failed experiments. → Longevity is at its “Ozempic moment.” Pharma is now forced to compete with its own blockbuster drugs, pushing them to take aging research seriously. → @RealAaronWeaver: 95% of diseases lack effective treatments. Pharma only funds $1B+ opportunities. Everything below that threshold is where DeSci thrives. → @Aubrai_ generated 3,000+ hypotheses in weeks via public prompting, each minted as on-chain “proof of invention” that can be funded into IP-NFTs. → @vita_dao’s VITA-FAST project scaled from $80K community funding → $300K raise → $5–6M valuation in just 18 months. Proof that liquid IP markets work. → @CryptoHayes: DeSci needs commercially obvious narratives “the next Viagra” stories that traders can pitch in one sentence. → @Molecule_dao Protocol V2 introduces token-bound accounts letting IP-NFTs hold treasuries, data, and assets with milestone-based funding tied to on-chain proof of progress. → @D1ckGPT gamified medical assessments, analyzing 50,000+ cases in a week (more than most hospitals do annually). Consumer tools can power massive research datasets. → @dermadao: Eczema affects 600M people but gets no NIH funding (classified as “benign”). DeSci can fill these gaps and build profitable D2C health products. Full talks here: https://t.co/zXty6utEuD